These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 22453153)

  • 1. Accelerated rejection of the second transplants of immunogenic tumor in mice under inhibition of indoleamine 2,3-dioxygenase activity by ethyl pyruvate.
    Vasilyeva ED; Kaledin V; Nikolin VP; Popova NA; Kirilyuk IA; Grigor'ev IA
    Exp Oncol; 2012; 34(1):66-8. PubMed ID: 22453153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel cancer therapy by skin delivery of indoleamine 2,3-dioxygenase siRNA.
    Yen MC; Lin CC; Chen YL; Huang SS; Yang HJ; Chang CP; Lei HY; Lai MD
    Clin Cancer Res; 2009 Jan; 15(2):641-9. PubMed ID: 19147770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression of indoleamine 2,3-dioxygenase in human endometrial carcinoma cells induces rapid tumor growth in a mouse xenograft model.
    Yoshida N; Ino K; Ishida Y; Kajiyama H; Yamamoto E; Shibata K; Terauchi M; Nawa A; Akimoto H; Takikawa O; Isobe K; Kikkawa F
    Clin Cancer Res; 2008 Nov; 14(22):7251-9. PubMed ID: 19010841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A new mechanism of tumor resistance to the immune system, based on tryptophan breakdown by indoleamine 2,3-dioxygenase].
    Van den Eynde B
    Bull Mem Acad R Med Belg; 2003; 158(7-9):356-63; discussion 364-5. PubMed ID: 15132006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor immune escape mediated by indoleamine 2,3-dioxygenase.
    Zamanakou M; Germenis AE; Karanikas V
    Immunol Lett; 2007 Aug; 111(2):69-75. PubMed ID: 17644189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Marrying immunotherapy with chemotherapy: why say IDO?
    Muller AJ; Prendergast GC
    Cancer Res; 2005 Sep; 65(18):8065-8. PubMed ID: 16166276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Research progress of indoleamine 2,3-dioxygenase inhibitors.
    Jiang T; Sun Y; Yin Z; Feng S; Sun L; Li Z
    Future Med Chem; 2015; 7(2):185-201. PubMed ID: 25686005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The immune tolerance of cancer is mediated by IDO that is inhibited by COX-2 inhibitors through regulatory T cells.
    Lee SY; Choi HK; Lee KJ; Jung JY; Hur GY; Jung KH; Kim JH; Shin C; Shim JJ; In KH; Kang KH; Yoo SH
    J Immunother; 2009 Jan; 32(1):22-8. PubMed ID: 19307990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual effects of indoleamine 2,3-dioxygenase inhibitors on the therapeutic effects of cyclophosphamide and cycloplatam on Ehrlich ascites tumor in mice.
    Bogdanova LA; Morozkova TS; Amitina SA; Mazhukin DG; Nikolin VP; Popova NA; Kaledin VI
    Bull Exp Biol Med; 2014 Aug; 157(4):506-9. PubMed ID: 25110094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Function of indoleamine 2,3-dioxygenase in corneal allograft rejection and prolongation of allograft survival by over-expression.
    Beutelspacher SC; Pillai R; Watson MP; Tan PH; Tsang J; McClure MO; George AJ; Larkin DF
    Eur J Immunol; 2006 Mar; 36(3):690-700. PubMed ID: 16482510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mouse model for allogeneic immune reaction against fetus recapitulates human pre-eclampsia.
    Nishizawa H; Hasegawa K; Suzuki M; Achiwa Y; Kato T; Saito K; Kurahashi H; Udagawa Y
    J Obstet Gynaecol Res; 2008 Feb; 34(1):1-6. PubMed ID: 18226121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of tryptanthrin derivatives as potent inhibitors of indoleamine 2,3-dioxygenase with therapeutic activity in Lewis lung cancer (LLC) tumor-bearing mice.
    Yang S; Li X; Hu F; Li Y; Yang Y; Yan J; Kuang C; Yang Q
    J Med Chem; 2013 Nov; 56(21):8321-31. PubMed ID: 24099220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Indoleamine 2,3-dioxygenase (IDO) activity influence tumor growth in the TRAMP prostate cancer model.
    Källberg E; Wikström P; Bergh A; Ivars F; Leanderson T
    Prostate; 2010 Sep; 70(13):1461-70. PubMed ID: 20687219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapeutic suppression of indoleamine 2,3-dioxygenase and tumor growth with ethyl pyruvate.
    Muller AJ; DuHadaway JB; Jaller D; Curtis P; Metz R; Prendergast GC
    Cancer Res; 2010 Mar; 70(5):1845-53. PubMed ID: 20160032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suppression of islet allogeneic immune response by indoleamine 2,3 dioxygenase-expressing fibroblasts.
    Jalili RB; Rayat GR; Rajotte RV; Ghahary A
    J Cell Physiol; 2007 Oct; 213(1):137-43. PubMed ID: 17477384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison study of different indoleamine-2,3 dioxygenase inhibitors from the perspective of pharmacodynamic effects.
    Jiang X; Li X; Zheng S; Du G; Ma J; Zhang L; Wang H; Tian J
    Int J Immunopathol Pharmacol; 2020; 34():2058738420950584. PubMed ID: 32962460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunological role of indoleamine 2,3-dioxygenase in rat liver allograft rejection and tolerance.
    Lin YC; Chen CL; Nakano T; Goto S; Kao YH; Hsu LW; Lai CY; Jawan B; Cheng YF; Tateno C; Yoshizato K
    J Gastroenterol Hepatol; 2008 Jul; 23(7 Pt 2):e243-50. PubMed ID: 17645734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IFN-gamma is the inducer of indoleamine 2,3-dioxygenase in allografted tumor cells undergoing rejection.
    Takikawa O; Habara-Ohkubo A; Yoshida R
    J Immunol; 1990 Aug; 145(4):1246-50. PubMed ID: 2116480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells.
    Brandacher G; Perathoner A; Ladurner R; Schneeberger S; Obrist P; Winkler C; Werner ER; Werner-Felmayer G; Weiss HG; Göbel G; Margreiter R; Königsrainer A; Fuchs D; Amberger A
    Clin Cancer Res; 2006 Feb; 12(4):1144-51. PubMed ID: 16489067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 4-Bromophenylhydrazinyl benzenesulfonylphenylureas as indoleamine 2,3-dioxygenase inhibitors with in vivo target inhibition and anti-tumor efficacy.
    Lin SY; Yeh TK; Song JS; Hung MS; Cheng MF; Liao FY; Li AS; Cheng SY; Lin LM; Chiu CH; Wu MH; Lin YJ; Hsiao W; Sun M; Wang YH; Huang CH; Tang YC; Chang HH; Huang ZT; Chao YS; Shih C; Pan SL; Wu SY; Kuo CC; Ueng SH
    Bioorg Chem; 2018 Apr; 77():600-607. PubMed ID: 29494816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.